News
Recently,2022 the results of the evaluation of the results of the annual survey and design of Hubei Province were released, and the National Pharmaceutical Project was won.4 awards. Among them, "Qilu Pharmaceutical Biomedical Industrial Park Bioengineering Park Project" won the first-class results, "Qingdao Yibang Biotechnology Industrial Park Phase III Construction Project" and "Hainan Haiyao Biomedical Industrial Park Project" won the second-class results, "Yuxi Zerun Biotechnology Co., Ltd. Cervical Cancer New Vaccine Industrialization Project" won the third-class results.
This time won four awards in one fell swoop, the National Medicine Project it is a concrete manifestation of continuously increasing the intensity of scientific and technological innovation and continuously improving the level of design excellence and comprehensive technical strength. Sinopharm Engineering will adhere to the mission of "committed to medical health and serving social development", continue to promote technological innovation, strive to create more high-quality and high-level design works, and contribute more to the promotion of industry progress.
of the (I) Qilu Pharmaceutical and Biopharmaceutical Industrial Park Project (First-class Achievement)
Project investment7.2 it is the first large-scale monoclonal antibody production workshop in China to be certified and put into use, which can be realized.10.8 million liters of cell culture production scale. The project design follows the principles of large-scale, low energy consumption and high efficiency, in strict accordance with
(II) Qingdao Yibang Biotechnology Industrial Park Phase III Construction Project(Second Class Results)
Total Project Investment9.3 billions of yuan, mainly built avian Influenza Inactivated Vaccine Workshop ( P3), P3 research and development quality inspection center and animal room, finished cold storage, etc. The production workshop and animal room of the project are designed according to the three-level biosafety protection standard, and adopt a complete set of biosafety prevention technology.2573 no. (Level 3 Biosafety Protection Standard for Veterinary Vaccine Manufacturers) (2017.8.31) and "veterinary drug production quality management standards (2020 annual Revision) (2020.4.21) (
(III) Hainan Haiyao Biopharmaceutical Industrial Park Project(Second Class Results)
Project investment7.2100 million yuan, total construction area85016 square meters, the production workshop design is positioned as a high-end preparation workshop, the design adopts a number of advanced technology and technical equipment, in the process flow and layout design, the use of unit modular design concept, greatly improving the production efficiency and flexibility of the device, saving construction investment. The project has passed the domestic GMP certification, and satisfy FDA and EUGMP the product quality is at the leading level of similar products in China, and has reached European and American standards.
(IV) Yuxi Zerun Biotechnology Co., Ltd. Cervical Cancer New Vaccine Industrialization Project(Third-class results)
Project investment3.4 billion yuan, has been built at the same time in line with China
(Contribution from Engineering and Technology Department)
Company News
